Search results for "C25"

showing 10 items of 566 documents

Prognostic role in common clinical practice of neutrophil-to-lymphocyte ratio in unselected bladder cancer

2020

Oncologymedicine.medical_specialtyNo parole chiaveBladder cancerbusiness.industryUrologylcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282Clinical PracticeInternal medicinemedicineNeutrophil to lymphocyte ratiobusinessEuropean Urology Open Science
researchProduct

Secretory breast carcinoma with metastatic sentinel lymph node

2006

Abstract Background Secretory mammary carcinoma is a rare breast neoplasia originally described in children but sometimes also found in adults. It presents a more favourable outcome than more common histological types of breast carcinoma; published literature in fact reports only a few cases with axillary lymph node metastases and only four cases with distant metastases. Clinical presentation In this paper we report a rare case of secretory breast carcinoma with axillary lymph node metastases in a 33-year-old woman. To our knowledge, this is the first case of secretory carcinoma involving biopsy of the sentinel lymph node and investigation of the e-cadherin expression. We found positivity f…

Oncologymedicine.medical_specialtyPathologySentinel lymph nodelcsh:SurgeryCase ReportSettore MED/08 - Anatomia Patologicalcsh:RC254-282Mammary carcinomasentinel lymph nodeSurgical oncologyInternal medicinemedicineLymph nodebusiness.industrylcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSecretory breast carcinomaSettore MED/18 - Chirurgia GeneraleLymphedemamedicine.anatomical_structureSecretory breast carcinoma; sentinel lymph node; metastases; e-cadherinOncologymetastaseSurgerybusinessBreast carcinomae-cadherinSecretory Breast CarcinomaWorld Journal of Surgical Oncology
researchProduct

Transarterial radioembolization for hepatocellular carcinoma: a review

2016

Rodolfo Sacco,1 Caterina Conte,2 Emanuele Tumino,1 Giuseppe Parisi,1 Sara Marceglia,3 Salvatore Metrangolo,1 Roberto Eggenhoffner,4 Giampaolo Bresci,1 Giuseppe Cabibbo,5 Luca Giacomelli4 1Department of Gastroenterology, Cisanello Hospital, Pisa, 2Endocrinology and Metabolic Diseases, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome, 3Department of Engineering and Architecture, University of Trieste, Trieste, 4Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, Genova University, Genoa, 5Section of Gastroenterology, DIBIMIS, University of Palermo, Palermo, Italy Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver canc…

Oncologymedicine.medical_specialtyReviewTransarterial RadioembolizationMalignancylcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicineMedicineTherapeutic strategyCause of deathbusiness.industryTreatment optionshepatocellular carcinomahepatocellular carcinoma; transarterial radioembolizationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseasesSafety profile030220 oncology & carcinogenesisHepatocellular carcinomatransarterial radioembolization030211 gastroenterology & hepatologybusinessLiver cancerhepatocellular carcinoma transarterial radioembolization
researchProduct

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

2012

Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to g…

Oncologymedicine.medical_specialtybusiness.industryFirst linemantle cell lymphomaCancerTreatment optionsmTOR-inhibitorReviewDiseasemedicine.diseaseBioinformaticslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282TemsirolimusClinical knowledgeOncologyInternal medicinetemsirolimusmedicineRefractory Mantle Cell LymphomaMantle cell lymphomabusinessmedicine.drugClinical Medicine Insights: Oncology
researchProduct

Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of ra…

2020

Oncologymedicine.medical_specialtylcsh:Diseases of the musculoskeletal systembusiness.industryMEDLINEEndocrine therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282Bone healthlaw.inventionBreast cancermedicine.anatomical_structureDenosumabOncologyRandomized controlled triallawProstateMeta-analysisInternal medicineCommentarymedicinelcsh:RC925-935businessmedicine.drugJournal of Bone Oncology
researchProduct

Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy

2017

The authors present a case of an 80-year-old Caucasian male with multiple gastric and rectal metastases from malignant melanoma presenting with hypochromic anemia as the sole symptom of disease without evidence of cutaneous and ocular tumor localization. The patient had a medical history positive for malignant lentigo melanoma of the occipital region of the scalp and early stage laryngeal squamous cell carcinoma and prostatic carcinoma treated with radiation therapy. The authors make some considerations on intestinal involvement by metastatic melanoma and discuss the choice of not treating with endoscopic procedures the gastric metastatic lesions most likely responsible for the clinical sig…

Oncologymedicine.medical_specialtymedicine.medical_treatmentCase ReportIpilimumabPembrolizumablcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaMedical historyStage (cooking)business.industryMelanomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseDermatologyRadiation therapyHypochromic anemiaOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessmelanoma rectal metastases immunotherapymedicine.drugCase Reports in Oncological Medicine
researchProduct

Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Gr…

2021

Many cancer patients use integrative therapies with a combination of natural products and diets. In the Western world, integrative medicine is often not shared with oncologists even during antineoplastic treatments. This behavior stems from the unmet needs of cancer patients who may feel oncologists’ underestimation of their symptoms and spiritual aspects. This case report demonstrates the potential harm of inadequate diet and nutraceutical intake in a 68-year-old woman with metastatic estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. Her care team recommended hormone therapy with abemaciclib plus fulvestrant. Her diarrhea started after 10 days of …

Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorCase ReportDiseaseBreast cancerInternal medicineEstrogen receptorMedicineRC254-282Fulvestrantbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerMetastatic breast cancermedicine.diseaseMetastatic breast cancerAbemaciclibOncologyDetoxifying dietNutraceuticalsHormone therapyIntegrative medicinebusinessmedicine.drugCase Reports in Oncology
researchProduct

Late-line treatment in metastatic gastric cancer: today and tomorrow.

2019

Survival for patients with unresectable advanced or recurrent gastric cancer (GC) remains poor and the historical lack of evidence-based therapeutic options after second-line therapy is reflected in current clinical guidelines for this condition. Despite uncertainty about optimal therapeutic strategies, further treatment is appropriate for some patients after failure of second line and may prolong survival. This approach has been reported in clinical trials and is becoming more common in real-world clinical settings. Several prognostic factors may increase the likelihood that a patient will be eligible for treatment in the third-line setting, including geographic location, status at diagno…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPopulationPembrolizumabReviewchemotherapylcsh:RC254-282law.inventiontrifluridine/tipiracilchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineeducationTipiracilnivolumabChemotherapyeducation.field_of_studybusiness.industryImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensClinical trialgastric cancer (GC)OncologychemistryimmunotherapypembrolizumabNivolumabbusinessTherapeutic advances in medical oncology
researchProduct

Mitotane Concentrations Influence Outcome in Patients With Advanced Adrenocortical Carcinoma

2020

Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated with mitotane for &ge

OncologymitotaneCancer Researchmedicine.medical_specialtyMultivariate analysisrecurrenceCombination therapyPrognosimedicine.medical_treatment030209 endocrinology & metabolismDiseaselcsh:RC254-282behavioral disciplines and activitiessurvivalArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenocortical carcinomaMitotaneIn patientadrenal cancerObjective responseadrenal cancer; mitotane; prognosis; recurrence; survivalChemotherapybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisprognosisbusinessAdrenal cancer Mitotane Prognosis Recurrence Survivalmedicine.drug
researchProduct

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

2021

Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De…

Oncologysorafenib.Cancer Management and ResearchhepatocarcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogenssorafeniblenvatinibneoplasmsdigestive system diseasesRC254-282Original ResearchCancer Management and Research
researchProduct